Back to Back Issues Page
Slow the Progression of Dry AMD with a Single Dose
October 30, 2019
Hello

Slow the Progression of Dry AMD with a Single Dose

While dry macular degeneration is the most common form of age related macular degeneration (AMD), most research is focused on treating wet AMD. However, an ophthalmology company that's developing gene therapies in the UK called Gyroscope Therapeutics has just launched its first Phase I/II clinical trial to slow the progression of central vision loss in patients with dry AMD.



The basis of their research involves the cascading effects of what is called the Complement System - complement system proteins, complement activators and complement regulatory proteins. These molecules stimulate and trigger inflammation and the progression of macular degeneration.

The first gene therapy clinical trial for the dry form of age related macular degeneration is being led by University of Oxford ophthalmology professor Dr. Robert MacLaren. He states, "There are currently limited treatments for dry AMD, which in many cases will progress to the wet form several years later. We now know a lot about the role of the complement system in AMD and also how to deliver gene therapies safely to the fovea in patients with good visual acuity. Hence it is logical now to explore early interventions that might have an impact in stopping progression of this disease."

Find out more about this dry macular degeneration study using gene therapy here:

Gene Therapy for Slowing the Progression of Dry AMD

Leslie Degner, RN, BSN

Better Health for Better Vision

www.WebRN-MacularDegeneration.com

Back to Back Issues Page